Suppressor microRNA-145 Is epigenetically regulated by promoter hypermethylation in esophageal squamous cell carcinoma

Anticancer Research

Volumn 35, Issue 9, 2015, Pages 4617-4624

  Harada, Kazuto ^a   Baba, Yoshifumi ^a   Ishimoto, Takatsugu ^a   Kosumi, Keisuke ^a   Tokunaga, Ryuma ^a   Izumi, Daisuke ^a   Ohuchi, Mayuko ^a   Nakamura, Kenichi ^a   Kiyozumi, Yuki ^a   Kurashige, Junji ^a   Iwagami, Shiro ^a   Miyamoto, Yuji ^a   Sakamoto, Yasuo ^a   Yoshida, Naoya ^a   Oki, Eiji ^b   Watanabe, Masayuki ^c   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Cancer epigenetics; DNA methylation; Esophageal squamous cell carcinoma; MicroRNA

Indexed keywords

BISULFITE; DECITABINE; GENOMIC DNA; MICRORNA 145; MICRORNA 145 5P; PROTEIN P53; UNCLASSIFIED DRUG; MICRORNA; MIRN145 MICRORNA, HUMAN;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DETERMINATION; DNA FLANKING REGION; DNA METHYLATION; EPIGENETICS; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; RNA ANALYSIS; RNA EXTRACTION; UPREGULATION; CPG ISLAND; DNA MICROARRAY; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MUCOSA; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MUCOUS MEMBRANE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC;

EID: 84939644749     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
2. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
3. Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y, Noushmehr H, Lange CP, van Dijk CM, Tollenaar RA, Van Den Berg D, and Laird PW: Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 44: 40-46, 2012.
4. Baba Y, Watanabe M, Murata A, Shigaki H, Miyake K, Ishimoto T, Iwatsuki M, Iwagami S, Yoshida N, Oki E, Sakamaki K, Nakao M, and Baba H: LINE1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma. Clin Cancer Res 20: 1114-1124, 2014.
5. Lopez-Serra P and Esteller M: DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31: 1609-1622, 2012.
6. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, and Jones PA: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443, 2006.
7. He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004.
8. Song JH and Meltzer SJ: MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 143: 35-47 e32, 2012.
9. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B, Meng X, Ma X, Luo M, Shao K, Li N, Qiu B, Mitchelson K, Cheng J, and He J: Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 68: 26-33, 2008.
10. Sachdeva M and Mo YY: miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2: 170-180, 2010.
11. Sobin LH, Gospodarowicz MK, Wittekind C, and International Union Against Cancer: TNM Classification of Malignant Tumours. Chichester, West Sussex, UK: Wiley-Blackwell, 2010.
12. Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K, Ida S, Nagai Y, Ishimoto T, Iwatsuki M, Sakamoto Y, Miyamoto Y, and Baba H: Pyrosequencing assay to measure LINE1 methylation level in esophageal squamous cell carcinoma. Ann Surg Oncol 19: 2726-2732, 2012.
13. Ishimoto T, Sugihara H, Watanabe M, Sawayama H, Iwatsuki M, Baba Y, Okabe H, Hidaka K, Yokoyama N, Miyake K, Yoshikawa M, Nagano O, Komohara Y, Takeya M, Saya H, and Baba H: Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation. Carcinogenesis 35: 1003-1011, 2014.
14. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, Tanaka Y, and Dahiya R: MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 32: 772-778, 2011.
15. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, and Kosik KS: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137: 647-658, 2009.
16. Chiou GY, Cherng JY, Hsu HS, Wang ML, Tsai CM, Lu KH, Chien Y, Hung SC, Chen YW, Wong CI, Tseng LM, Huang PI, Yu CC, Hsu WH, and Chiou SH: Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release 159: 240-250, 2012.
17. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, and Mo YY: p53 represses c-MYC through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106: 3207-3212, 2009.
18. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, and Miyazono K: Modulation of microRNA processing by p53. Nature 460: 529-533, 2009.
19. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, Forte S, De Maria R, and Ricci-Vitiani L: Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 32: 4806-4813, 2013.
20. Zhu Z, Xu T, Wang L, Wang X, Zhong S, Xu C, and Shen Z: MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. FEBS Lett 588: 3180-3185, 2014.
21. Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, Chiou GY, Chou MY, and Chiou SH: miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL6-mediated paracrine effects in head and neck cancer. Cancer Res 73: 3425-3440, 2013.
22. Sachdeva M Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010; 70: 378-87.
23. Sachdeva M and Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70: 378-387, 2010.
24. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, and Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
25. Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, and Huang TH: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 69: 9038-9046, 2009.
26. Cui X, Zhao Z, Liu D, Guo T, Li S, Hu J, Liu C, Yang L, Cao Y, Jiang J, Liang W, Liu W, Li S, Wang L, Wang L, Gu W, Wu C, Chen Y, and Li F: Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma. J Exp Clin Cancer Res 33: 20, 2014.
27. Chen X, Hu H, Guan X, Xiong G, Wang Y, Wang K, Li J, Xu X, Yang K, and Bai Y: CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer 130: 1607-1613, 2012.
28. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, Qin YR, and Guan XY: MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 61: 33-42, 2012.
29. Inoue N, Isomoto H, Matsushima K, Hayashi T, Kunizaki M, Hidaka S, Machida H, Mitsutake N, Nanashima A, Takeshima F, Nakayama T, Ohtsuru A, Nakashima M, Nagayasu T, Yamashita S, Nakao K, and Kohno S: Down-regulation of microRNA 10a expression in esophageal squamous cell carcinoma cells. Oncol Lett 1: 527-531, 2010.
30. Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, Carmona J, Carrere J, Vidal A, Aytes A, Puertas S, Ropero S, Kalluri R, Croce CM, Calin GA, and Esteller M: Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci USA 108: 4394-4399, 2011.
31. Haapa-Paananen S, Chen P, Hellstrom K, Kohonen P, Hautaniemi S, Kallioniemi O, and Perala M: Functional profiling of precursor MicroRNAs identifies microRNAs essential for glioma proliferation. PLoS One 8: e60930, 2013.
32. Tang M, Lin L, Cai H, Tang J, and Zhou Z: MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma. Onco Targets Ther 6: 833-838, 2013.
33. Schee K, Boye K, Abrahamsen TW, Fodstad O, and Flatmark K: Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12: 505, 2012.
34. Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH, Nakajima K, Takiguchi S, Fujiwara Y, Mori M, and Doki Y: Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the AKT signaling pathway. Clin Cancer Res 17: 3029-3038, 2011.
35. Yoo CB and Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50, 2006.
36. Muller CI, Ruter B, Koeffler HP, and Lubbert M: DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm Biotechnol 7: 315-321, 2006.
37. Ko MA, Zehong G, Virtanen C, Guindi M, Waddell TK, Keshavjee S, and Darling GE: MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann Thorac Surg 94: 1094-1102, 2012.
38. Tanaka K, Miyata H, Yamasaki M, Sugimura K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, and Doki Y: Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol 20 Suppl 3: S607-615, 2013.
39. Wang F, Xia J, Wang N, and Zong H: miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc. Onkologie 36: 754-758, 2013.
40. Liu R, Liao J, Yang M, Sheng J, Yang H, Wang Y, Pan E, Guo W, Pu Y, Kim SJ, and Yin L: The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One 7: e33987, 2012.